Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($1.23), $0.77 better than the analyst estimate of ($2.00). Revenue for the quarter came in at $10.13 million versus the consensus estimate of $10.38 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.